LT4251B - Carbamazepine medicament with retarded active substance release - Google Patents
Carbamazepine medicament with retarded active substance release Download PDFInfo
- Publication number
- LT4251B LT4251B LT97-012A LT97012A LT4251B LT 4251 B LT4251 B LT 4251B LT 97012 A LT97012 A LT 97012A LT 4251 B LT4251 B LT 4251B
- Authority
- LT
- Lithuania
- Prior art keywords
- carbamazepine
- film
- ratio
- forming agent
- process according
- Prior art date
Links
- 229960000623 carbamazepine Drugs 0.000 title claims abstract description 43
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000013543 active substance Substances 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 title abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 238000000576 coating method Methods 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 7
- 229920003161 Eudragit® RS 30 D Polymers 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 229920000120 polyethyl acrylate Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000004922 lacquer Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 235000013769 triethyl citrate Nutrition 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002966 varnish Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 abstract description 9
- 239000004815 dispersion polymer Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 150000004683 dihydrates Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UPTJXAHTRRBMJE-UHFFFAOYSA-N benzo[b][1]benzazepine-11-carboxamide;dihydrate Chemical compound O.O.C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 UPTJXAHTRRBMJE-UHFFFAOYSA-N 0.000 description 1
- -1 carbamazepine dihydrates Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical class C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19944423078 DE4423078B4 (de) | 1994-07-01 | 1994-07-01 | Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT97012A LT97012A (en) | 1997-08-25 |
| LT4251B true LT4251B (en) | 1997-12-29 |
Family
ID=6522000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT97-012A LT4251B (en) | 1994-07-01 | 1997-01-30 | Carbamazepine medicament with retarded active substance release |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5888545A (pl) |
| EP (1) | EP0768882B1 (pl) |
| JP (1) | JPH10502358A (pl) |
| KR (1) | KR100344477B1 (pl) |
| CN (1) | CN1101191C (pl) |
| AT (1) | ATE169818T1 (pl) |
| BG (1) | BG62794B1 (pl) |
| BR (1) | BR9508202A (pl) |
| CA (1) | CA2194216A1 (pl) |
| CZ (1) | CZ288028B6 (pl) |
| DE (2) | DE4423078B4 (pl) |
| DK (1) | DK0768882T3 (pl) |
| EE (1) | EE03954B1 (pl) |
| ES (1) | ES2122630T3 (pl) |
| GE (1) | GEP19991819B (pl) |
| HU (1) | HU221486B (pl) |
| LT (1) | LT4251B (pl) |
| LV (1) | LV11820B (pl) |
| PL (1) | PL180979B1 (pl) |
| RU (1) | RU2141825C1 (pl) |
| SK (1) | SK282303B6 (pl) |
| UA (1) | UA32598C2 (pl) |
| WO (1) | WO1996001112A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162466A (en) * | 1999-04-15 | 2000-12-19 | Taro Pharmaceutical Industries Ltd. | Sustained release formulation of carbamazepine |
| GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| RU2240798C1 (ru) * | 2003-06-25 | 2004-11-27 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая противосудорожным и психотропным действием, и способ ее получения |
| RU2007143556A (ru) * | 2005-04-25 | 2009-06-10 | ТЕВА ФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. (US) | Композиции с пролонгированным высвобождением |
| JP2009507047A (ja) * | 2005-09-09 | 2009-02-19 | ラボファーム インコーポレイテッド | 持続性薬物放出組成物 |
| WO2007048220A2 (en) * | 2005-09-09 | 2007-05-03 | Labopharm Inc. | Trazodone composition for once a day adminisitiation |
| US20070160960A1 (en) * | 2005-10-21 | 2007-07-12 | Laser Shot, Inc. | System and method for calculating a projectile impact coordinates |
| RU2361591C1 (ru) * | 2007-10-03 | 2009-07-20 | Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") | Противосудорожное лекарственное средство |
| FR2940910A1 (fr) * | 2009-01-09 | 2010-07-16 | Vetoquinol Sa | Nouveau comprime a base de s-adenosyl-methionine |
| CN105997916A (zh) * | 2016-07-19 | 2016-10-12 | 南京正宽医药科技有限公司 | 一种卡马西平片及其制备方法 |
| CN108125922A (zh) * | 2018-01-14 | 2018-06-08 | 上海安必生制药技术有限公司 | 一种卡马西平口服缓释制剂及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3725824A1 (de) | 1986-08-07 | 1988-02-11 | Ciba Geigy Ag | Orales therapeutisches system mit systemischer wirkung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| SE8203953D0 (sv) * | 1982-06-24 | 1982-06-24 | Astra Laekemedel Ab | Pharmaceutical mixture |
| DK151608C (da) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
| IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| US5326572A (en) * | 1989-03-23 | 1994-07-05 | Fmc Corporation | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions |
-
1994
- 1994-07-01 DE DE19944423078 patent/DE4423078B4/de not_active Expired - Fee Related
-
1995
- 1995-06-22 JP JP8503611A patent/JPH10502358A/ja not_active Ceased
- 1995-06-22 CA CA002194216A patent/CA2194216A1/en not_active Abandoned
- 1995-06-22 ES ES95922407T patent/ES2122630T3/es not_active Expired - Lifetime
- 1995-06-22 SK SK1646-96A patent/SK282303B6/sk not_active IP Right Cessation
- 1995-06-22 DE DE59503283T patent/DE59503283D1/de not_active Expired - Lifetime
- 1995-06-22 AT AT95922407T patent/ATE169818T1/de active
- 1995-06-22 WO PCT/DE1995/000805 patent/WO1996001112A1/de not_active Ceased
- 1995-06-22 RU RU97101469A patent/RU2141825C1/ru active
- 1995-06-22 KR KR1019960707549A patent/KR100344477B1/ko not_active Expired - Lifetime
- 1995-06-22 GE GEAP19953512A patent/GEP19991819B/en unknown
- 1995-06-22 US US08/776,266 patent/US5888545A/en not_active Expired - Lifetime
- 1995-06-22 EP EP95922407A patent/EP0768882B1/de not_active Expired - Lifetime
- 1995-06-22 PL PL95317996A patent/PL180979B1/pl unknown
- 1995-06-22 CZ CZ19963826A patent/CZ288028B6/cs not_active IP Right Cessation
- 1995-06-22 CN CN95193915A patent/CN1101191C/zh not_active Expired - Fee Related
- 1995-06-22 UA UA97010403A patent/UA32598C2/uk unknown
- 1995-06-22 HU HU9603565A patent/HU221486B/hu unknown
- 1995-06-22 EE EE9600202A patent/EE03954B1/xx unknown
- 1995-06-22 BR BR9508202A patent/BR9508202A/pt not_active Application Discontinuation
- 1995-06-22 DK DK95922407T patent/DK0768882T3/da active
-
1996
- 1996-12-28 BG BG101080A patent/BG62794B1/bg unknown
-
1997
- 1997-01-30 LT LT97-012A patent/LT4251B/lt not_active IP Right Cessation
- 1997-01-30 LV LVP-97-13A patent/LV11820B/lv unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3725824A1 (de) | 1986-08-07 | 1988-02-11 | Ciba Geigy Ag | Orales therapeutisches system mit systemischer wirkung |
Non-Patent Citations (1)
| Title |
|---|
| K. LEHMANN ET AL.: "Fast-disintegrating tablets with controlled active substance release", PHARM. IND., 1993, pages 940 - 947 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930003114B1 (ko) | 2상성의 방출 단면을 가진 제어 방출되는 경구용 제제의 제조방법 | |
| AU2001255509B2 (en) | Taste masking coating composition | |
| JP2823605B2 (ja) | 安定な遅延医薬剤型 | |
| JPH05500674A (ja) | 医薬製剤 | |
| PL192961B1 (pl) | Sposób wytwarzania doustnej kompozycji farmaceutycznej i doustna kompozycja farmaceutyczna | |
| HU203200B (en) | Process for producing oral pharmaceutical compositions comprising acid-sensitive benzimidazole derivatives | |
| JPS6229514A (ja) | 医薬活性物質の遅延放出形粒状物及びその製造方法 | |
| JPH07145052A (ja) | 良好な溶解特性を有する医薬組成物 | |
| AU765765B2 (en) | Particles coated with granulated crystalline ibuprofen | |
| LT4251B (en) | Carbamazepine medicament with retarded active substance release | |
| PT93029A (pt) | Processo para a preparacao de uma composicao contendo acido 5-(2,5- dimetilfenoxi)-2,2-dimetil-pentanoico (gemfibrozilo) de libertacao modificada | |
| MXPA06004700A (es) | Formulacion conteniendo agente farmaceutico comprendiendo un recubrimiento. | |
| JPH0632739A (ja) | 胆汁酸の小ペレットを含有する徐放性経口薬剤組成物 | |
| WO2017037741A1 (en) | Compact solid dosage form of aspirin and clopidogrel | |
| US20020076444A1 (en) | Novel method for obtaining microspheres and resulting products | |
| EP0751771A1 (en) | Pharmaceutical formulations containing beta-lactam antibiotics and an alkyl sulphate surfactant | |
| JPH0157090B2 (pl) | ||
| JP2002370968A (ja) | 薬物含有徐放性顆粒およびそれを含む錠剤 | |
| Pareek et al. | InstaSpheres TA (Tartaric acid) as functional starter core for extended release formulations | |
| UA127768C2 (uk) | Спосіб отримання багатоелементної пероральної дозованої лікарської форми з модифікованим вивільненням сукцинату доксиламіну і гідрохлориду піридоксину | |
| JPS6141325B2 (pl) | ||
| Deasy et al. | Correlation of surface characteristics with ease of production and in vitro release of sodium salicylate from various enteric coated microcapsules prepared by pan coating | |
| JP2001151671A (ja) | 突起付き粒子製剤 | |
| BG64499B1 (bg) | Фармацевтичен адхезивен състав за стомаха и/или дуоденума | |
| HK1100424B (en) | Oral preparations and process for production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Free format text: 20021007 * AWD PHARMA GMBH&CO.KG,DE |
|
| PD9A | Change of patent owner |
Owner name: AWD. PHARMA GMBH & CO. KG, DE Effective date: 20030113 |
|
| MK9A | Expiry of a patent |
Effective date: 20150622 |